- Home
- ROIV vs OLED Comparison
ROIV vs OLED Comparison
Compare ROIV & OLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- OLED
- Stock Information
- Founded
- ROIV 2014
- OLED 1985
- Country
- ROIV United Kingdom
- OLED United States
- Employees
- ROIV N/A
- OLED N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- OLED Semiconductors
- Sector
- ROIV Health Care
- OLED Technology
- Exchange
- ROIV Nasdaq
- OLED Nasdaq
- Market Cap
- ROIV 8.4B
- OLED 7.2B
- IPO Year
- ROIV N/A
- OLED 1992
- Fundamental
- Price
- ROIV $10.91
- OLED $145.96
- Analyst Decision
- ROIV Buy
- OLED Strong Buy
- Analyst Count
- ROIV 4
- OLED 7
- Target Price
- ROIV $17.50
- OLED $190.43
- AVG Volume (30 Days)
- ROIV 5.5M
- OLED 680.2K
- Earning Date
- ROIV 05-29-2025
- OLED 05-01-2025
- Dividend Yield
- ROIV N/A
- OLED 1.23%
- EPS Growth
- ROIV N/A
- OLED 4.58
- EPS
- ROIV N/A
- OLED 4.81
- Revenue
- ROIV $122,585,000.00
- OLED $648,702,000.00
- Revenue This Year
- ROIV N/A
- OLED $5.75
- Revenue Next Year
- ROIV N/A
- OLED $10.76
- P/E Ratio
- ROIV N/A
- OLED $30.39
- Revenue Growth
- ROIV 140.04
- OLED 6.13
- 52 Week Low
- ROIV $8.73
- OLED $103.70
- 52 Week High
- ROIV $13.06
- OLED $237.00
- Technical
- Relative Strength Index (RSI)
- ROIV 52.03
- OLED 55.03
- Support Level
- ROIV $10.58
- OLED $139.13
- Resistance Level
- ROIV $11.77
- OLED $156.06
- Average True Range (ATR)
- ROIV 0.33
- OLED 4.19
- MACD
- ROIV -0.04
- OLED 0.64
- Stochastic Oscillator
- ROIV 28.57
- OLED 37.04
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.